Harbin Pharmaceutical Group Co (SHSE:600664) Institutional Ownership: 1.81% (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600664 Harbin Pharmaceutical Group Co Ltd SHSE:600664
57 GF Score
Price ¥8.71
GF Value ¥3.64
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Harbin Pharmaceutical Group Co Institutional Ownership?

Harbin Pharmaceutical Group Co SHSE:600664 +6.48% 57 Institutional Ownership is 1.81% as of Aug. 27, 2026. GuruFocus rates SHSE:600664 with a GF Score™ of 57/100 and a GF Value™ of ¥3.64 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Harbin Pharmaceutical Group Co's institutional ownership is 1.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Harbin Pharmaceutical Group Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Harbin Pharmaceutical Group Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Harbin Pharmaceutical Group Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Harbin Pharmaceutical Group Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harbin Pharmaceutical Group Co Institutional Ownership Chart

Harbin Pharmaceutical Group Co Historical Data

The historical data trend for Harbin Pharmaceutical Group Co can be seen below:

2025-08-31 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 3.01 3.01 3.01 1.84 1.84 1.84 1.82 1.82 1.82 1.81
SHSE:600664
57GF Score
Harbin Pharmaceutical Group Co Ltd SHSE:600664
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harbin Pharmaceutical Group Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.81% mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a Institutional Ownership of 1.81% as of Aug. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Harbin Pharmaceutical Group Co and its competitors.
Is Harbin Pharmaceutical Group Co's Institutional Ownership too high?
Harbin Pharmaceutical Group Co's current Institutional Ownership is 1.81%. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Institutional Ownership compare to ZTS?
Harbin Pharmaceutical Group Co's Institutional Ownership of 1.81% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Harbin Pharmaceutical Group Co and its competitors. Harbin Pharmaceutical Group Co's current Institutional Ownership is 1.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.64, compared to a current price of ¥8.71 — trading 139.3% above its estimated fair value. The current Institutional Ownership is 1.81%. Harbin Pharmaceutical Group Co's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Institutional Ownership is 1.81% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?

Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥8.71 is trading 139.3% above its estimated GF Value™ of ¥3.64. GuruFocus considers Harbin Pharmaceutical Group Co to be Significantly Overvalued.

Key valuation signals for SHSE:600664:

  • Institutional Ownership: 1.81%
  • GF Value™: ¥3.64 vs. price of ¥8.71 (139.3% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harbin Pharmaceutical Group Co Business Description

Address Xi\'an Street West, People \'s Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
57GF Score

Get the complete analysis for SHSE:600664

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.71
Price
¥3.64
GF Value